McKesson Corporation $MCK Shares Acquired by Rafferty Asset Management LLC

Rafferty Asset Management LLC boosted its holdings in McKesson Corporation (NYSE:MCK) by 4.4% in the third quarter, according to its most recent Form 13F filing with the SEC. The fund owned 13,807 shares of the company’s stock after purchasing an additional 583 shares during the period. Rafferty Asset Management LLC’s holdings in McKesson were worth $10,666,000 at the end of the most recent reporting period.

Several other hedge funds and other institutional investors also recently bought and sold shares of MCK. J.W. Cole Advisors Inc. raised its position in shares of McKesson by 35.3% during the 3rd quarter. J.W. Cole Advisors Inc. now owns 5,089 shares of the company’s stock valued at $3,931,000 after acquiring an additional 1,329 shares in the last quarter. Private Wealth Partners LLC raised its holdings in shares of McKesson by 5.6% during the third quarter. Private Wealth Partners LLC now owns 31,841 shares of the company’s stock worth $24,598,000 after purchasing an additional 1,682 shares during the period. AlphaQuest LLC lifted its position in shares of McKesson by 91.2% in the 3rd quarter. AlphaQuest LLC now owns 1,767 shares of the company’s stock worth $1,365,000 after buying an additional 843 shares during the last quarter. CW Advisors LLC lifted its position in shares of McKesson by 282.5% in the 2nd quarter. CW Advisors LLC now owns 11,008 shares of the company’s stock worth $8,067,000 after buying an additional 8,130 shares during the last quarter. Finally, Envestnet Asset Management Inc. boosted its holdings in shares of McKesson by 12.4% in the 3rd quarter. Envestnet Asset Management Inc. now owns 330,647 shares of the company’s stock valued at $255,438,000 after buying an additional 36,451 shares during the period. 85.07% of the stock is currently owned by hedge funds and other institutional investors.

Insider Transactions at McKesson

In other McKesson news, Director Maria Martinez sold 349 shares of the company’s stock in a transaction that occurred on Thursday, February 19th. The stock was sold at an average price of $939.87, for a total value of $328,014.63. Following the completion of the sale, the director directly owned 301 shares in the company, valued at $282,900.87. This represents a 53.69% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, EVP Thomas L. Rodgers sold 276 shares of the stock in a transaction on Monday, January 5th. The shares were sold at an average price of $816.18, for a total value of $225,265.68. Following the transaction, the executive vice president directly owned 2,268 shares of the company’s stock, valued at approximately $1,851,096.24. The trade was a 10.85% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders sold 1,143 shares of company stock worth $1,046,070 in the last three months. 0.08% of the stock is currently owned by company insiders.

McKesson Stock Performance

Shares of MCK stock opened at $984.61 on Monday. McKesson Corporation has a 1 year low of $621.88 and a 1 year high of $987.37. The firm has a market capitalization of $120.60 billion, a PE ratio of 28.32, a price-to-earnings-growth ratio of 1.59 and a beta of 0.38. The stock has a fifty day moving average of $868.77 and a two-hundred day moving average of $807.56.

McKesson (NYSE:MCK) last posted its quarterly earnings data on Wednesday, February 4th. The company reported $9.34 earnings per share for the quarter, topping the consensus estimate of $9.19 by $0.15. The business had revenue of $106.16 billion during the quarter, compared to the consensus estimate of $105.98 billion. McKesson had a net margin of 1.09% and a negative return on equity of 338.97%. The company’s quarterly revenue was up 11.4% compared to the same quarter last year. During the same quarter in the prior year, the company posted $8.03 earnings per share. McKesson has set its FY 2026 guidance at 38.800-39.200 EPS. Equities research analysts predict that McKesson Corporation will post 32.77 earnings per share for the current fiscal year.

McKesson Dividend Announcement

The business also recently disclosed a quarterly dividend, which will be paid on Wednesday, April 1st. Investors of record on Monday, March 2nd will be paid a dividend of $0.82 per share. This represents a $3.28 dividend on an annualized basis and a dividend yield of 0.3%. The ex-dividend date is Monday, March 2nd. McKesson’s dividend payout ratio (DPR) is currently 9.43%.

Analysts Set New Price Targets

MCK has been the topic of a number of recent research reports. JPMorgan Chase & Co. raised their target price on shares of McKesson from $983.00 to $1,107.00 and gave the stock an “overweight” rating in a report on Tuesday, February 10th. Evercore reissued an “outperform” rating and issued a $1,000.00 price target on shares of McKesson in a report on Thursday, November 6th. TD Cowen boosted their price objective on McKesson from $1,000.00 to $1,012.00 and gave the company a “buy” rating in a research report on Thursday, February 5th. Morgan Stanley reaffirmed an “overweight” rating and issued a $966.00 target price on shares of McKesson in a research report on Thursday, January 29th. Finally, Zacks Research downgraded shares of McKesson from a “strong-buy” rating to a “hold” rating in a report on Tuesday, November 25th. Thirteen investment analysts have rated the stock with a Buy rating and four have assigned a Hold rating to the company’s stock. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and an average price target of $943.50.

McKesson Company Profile

McKesson Corporation (NYSE: MCK) is a global healthcare services and distribution company that supplies pharmaceuticals, medical-surgical products and health care technology solutions. Founded in 1833 and headquartered in Irving, Texas, McKesson operates across the drug distribution and healthcare services value chain, connecting manufacturers, pharmacies, hospitals and health systems to help manage the movement of medicines and clinical supplies.

The company’s core activities include pharmaceutical wholesale distribution and logistics, specialty pharmacy services, and the provision of medical-surgical supplies to acute and non-acute care providers.